8,104 results match your criteria Brainstem Gliomas


Brainstem biopsy in pediatric diffuse intrinsic pontine glioma in the era of precision medicine: the INFORM study experience.

Eur J Cancer 2019 Apr 22;114:27-35. Epub 2019 Apr 22.

Hopp Children's Cancer Center Heidelberg (KiTZ), Heidelberg, Germany; German Cancer Consortium (DKTK), German Cancer Research Center (DKFZ), Heidelberg, Germany; Department of Pediatric Oncology, Hematology & Immunology, Heidelberg University Hospital, Heidelberg, Germany; Clinical Cooperation Unit Pediatric Oncology, German Cancer Research Center (DKFZ), Heidelberg, Germany. Electronic address:

Purpose: Diffuse intrinsic pontine glioma (DIPG) is a highly aggressive paediatric brain tumour with fatal outcome. The Individualised Therapy For Relapsed Malignancies In Childhood (INFORM) registry study offers comprehensive molecular profiling of high-risk tumours to identify target alterations for potential precision therapy. We analysed molecular characteristics and clinical data after brainstem biopsy of all enrolled newly diagnosed DIPGs. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S09598049193022
Publisher Site
http://dx.doi.org/10.1016/j.ejca.2019.03.019DOI Listing
April 2019
1 Read

Twenty-three years follow-up after low-dose Gamma Knife surgery of a brainstem juvenile pilocytic astrocytoma: a case report and review of the literature.

Childs Nerv Syst 2019 Apr 17. Epub 2019 Apr 17.

Division of Neurosurgery, National University Hospital, Singapore, Singapore.

Juvenile pilocytic astrocytoma (JPA) is a World Health Organization (WHO) grade I tumor that is the commonest to occur in the 0-19 age group, with an excellent prognosis of 96% 10-year survival in pediatric patients. Complete resection is the treatment of choice for JPAs. However, this is not always feasible due to the location of certain tumors, and the management following subtotal resection is controversial. Read More

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s00381-019-04147-7
Publisher Site
http://dx.doi.org/10.1007/s00381-019-04147-7DOI Listing
April 2019
2 Reads

Dorsally exophytic glioblastoma of the pons.

BMJ Case Rep 2019 Apr 16;12(4). Epub 2019 Apr 16.

Departamento de Especialidades Cirúrgicas, Universidade Federal do Rio de Janeiro Hospital Universitario Clementino Fraga Filho, Rio de Janeiro, Brazil.

Brainstem gliomas are rare tumours in adults, accounting for only 1%-2% of all intracranial gliomas. They are recognised as a heterogeneous group, in which most are malignant tumours. Brainstem gliomas are classified into four major groups according to the growth pattern on imaging, namely diffuse, focal, exophytic and cervicomedullary. Read More

View Article

Download full-text PDF

Source
http://casereports.bmj.com/lookup/doi/10.1136/bcr-2018-22810
Publisher Site
http://dx.doi.org/10.1136/bcr-2018-228105DOI Listing
April 2019
2 Reads

Next-Generation Hedgehog/GLI Pathway Inhibitors for Cancer Therapy.

Cancers (Basel) 2019 Apr 15;11(4). Epub 2019 Apr 15.

Department of Biosciences, Paris-Lodron University of Salzburg, Cancer Cluster Salzburg, Hellbrunner Strasse 34, 5020 Salzburg, Austria.

The Hedgehog/Glioma-associated oncogene homolog (HH/GLI) signaling pathway regulates self-renewal of rare and highly malignant cancer stem cells (CSC), which have been shown to account for the initiation and maintenance of tumor growth as well as for drug resistance, metastatic spread and relapse. Efficacious therapeutic approaches targeting CSC pathways, such as HH/GLI signaling in combination with chemo, radiation or immunotherapy are, therefore, of high medical need. Pharmacological inhibition of HH/GLI pathway activity represents a promising approach to eliminate malignant CSC. Read More

View Article

Download full-text PDF

Source
https://www.mdpi.com/2072-6694/11/4/538
Publisher Site
http://dx.doi.org/10.3390/cancers11040538DOI Listing
April 2019
1 Read

Differential Expression of Wilms' Tumor Protein in Diffuse Intrinsic Pontine Glioma.

J Neuropathol Exp Neurol 2019 May;78(5):380-388

Children's National Health System, Center for Genetic Medicine Research, Washington, District of Columbia.

Diffuse intrinsic pontine gliomas (DIPGs) are deadly tumors comprising 10%-15% of all childhood CNS cancers. Standard treatment is considered palliative and prognosis is near universal mortality. DIPGs have been classified into genomic subtypes based on histone variants with the lysine to methionine mutation on position 27 of histone tails (K27M). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/jnen/nlz021DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6467196PMC
May 2019
2 Reads
3.797 Impact Factor

Pathological and Molecular Features of Glioblastoma and Its Peritumoral Tissue.

Cancers (Basel) 2019 Apr 3;11(4). Epub 2019 Apr 3.

Istituto di Istologia ed Embriologia, Università Cattolica del Sacro Cuore, Fondazione Policlinico Universitario "Agostino Gemelli", IRCCS, 00168 Roma, Italy.

Glioblastoma (GBM) is one of the most aggressive and lethal human brain tumors. At present, GBMs are divided in primary and secondary on the basis of the mutational status of the isocitrate dehydrogenase (IDH) genes. In addition, IDH1 and IDH2 mutations are considered crucial to better define the prognosis. Read More

View Article

Download full-text PDF

Source
https://www.mdpi.com/2072-6694/11/4/469
Publisher Site
http://dx.doi.org/10.3390/cancers11040469DOI Listing
April 2019
2 Reads

Incidence trends of adult malignant brain tumors in Finland, 1990-2016.

Acta Oncol 2019 Apr 15:1-7. Epub 2019 Apr 15.

b Faculty of Social Sciences , University of Tampere , Tampere , Finland.

Background: Several studies have reported increased incidence trends of malignant gliomas in the late 1900s with a plateau in the 2000s, but also some recent increases have been reported. The purpose of our study was to analyze incidence trends of malignant gliomas in Finland by morphology and tumor location.

Material And Methods: Data on 4730 malignant glioma patients were obtained from case notifications to the nationwide, population-based Finnish Cancer Registry (FCR), and less detailed data on 3590 patients up to 2016. Read More

View Article

Download full-text PDF

Source
https://www.tandfonline.com/doi/full/10.1080/0284186X.2019.1
Publisher Site
http://dx.doi.org/10.1080/0284186X.2019.1603396DOI Listing
April 2019
2 Reads

Single-Cell Transcriptomics Uncovers Glial Progenitor Diversity and Cell Fate Determinants during Development and Gliomagenesis.

Cell Stem Cell 2019 Mar 23. Epub 2019 Mar 23.

Department of Pediatrics, Brain Tumor Center, Division of Experimental Hematology and Cancer Biology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH 45229, USA; Key Laboratory of Birth Defects, Children's Hospital of Fudan University, Shanghai 201102, China. Electronic address:

The identity and degree of heterogeneity of glial progenitors and their contributions to brain tumor malignancy remain elusive. By applying lineage-targeted single-cell transcriptomics, we uncover an unanticipated diversity of glial progenitor pools with unique molecular identities in developing brain. Our analysis identifies distinct transitional intermediate states and their divergent developmental trajectories in astroglial and oligodendroglial lineages. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.stem.2019.03.006DOI Listing

NT5DC2 promotes tumorigenicity of glioma stem-like cells by upregulating fyn.

Cancer Lett 2019 Apr 10;454:98-107. Epub 2019 Apr 10.

State Key Laboratory of Proteomics, Institute of Basic Medical Sciences, National Center of Biomedical Analysis, Beijing, 100850, China. Electronic address:

Glioblastoma (GBM) is an incurable primary brain tumor that is highly resistant to current treatments. Glioma stem-like cells (GSCs) are an aggressive population of glioma cells that not only initiate malignant growth, but also promote therapeutic resistance. Thus, targeting GSCs is critical for improving GBM treatment and ensuring complete eradication of the tumor. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.canlet.2019.04.003DOI Listing
April 2019
5 Reads

Roles of Extracellular Vesicles in High-Grade Gliomas: Tiny Particles with Outsized Influence.

Authors:
Michael W Graner

Annu Rev Genomics Hum Genet 2019 Apr 12. Epub 2019 Apr 12.

Department of Neurosurgery, Anschutz Medical Campus, University of Colorado Denver, Aurora, Colorado 80045, USA; email:

High-grade gliomas, particularly glioblastomas (grade IV), are devastating diseases with dismal prognoses; afflicted patients seldom live longer than 15 months, and their quality of life suffers immensely. Our current standard-of-care therapy has remained essentially unchanged for almost 15 years, with little new therapeutic progress.We desperately need a better biologic understanding of these complicated tumors in a complicated organ. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1146/annurev-genom-083118-015324DOI Listing
April 2019
1 Read

Pathogenic mutations in neurofibromin identifies a leucine-rich domain regulating glioma cell invasiveness.

Oncogene 2019 Apr 9. Epub 2019 Apr 9.

Molecular Neurotherapeutics Laboratory, National Neuroscience Institute, Singapore, 308433, Singapore.

Glioblastoma (GBM) is the most aggressive tumor of the brain. NF1, a tumor suppressor gene and RAS-GTPase, is one of the highly mutated genes in GBM. Dysregulated NF1 expression promotes cell invasion, proliferation, and tumorigenesis. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41388-019-0809-3DOI Listing
April 2019
4 Reads

Brain Region-Specific Gene Signatures Revealed by Distinct Astrocyte Subpopulations Unveil Links to Glioma and Neurodegenerative Diseases.

eNeuro 2019 Mar-Apr;6(2). Epub 2019 Apr 2.

The Vivian L. Smith Department of Neurosurgery, McGovern Medical School, University of Texas Health Science Center at Houston, Houston, Texas 77030.

Currently, there are no effective treatments for glioma or for neurodegenerative diseases because of, in part, our limited understanding of the pathophysiology and cellular heterogeneity of these diseases. Mounting evidence suggests that astrocytes play an active role in the pathogenesis of these diseases by contributing to a diverse range of pathophysiological states. In a previous study, five molecularly distinct astrocyte subpopulations from three different brain regions were identified. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1523/ENEURO.0288-18.2019DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6449165PMC

Lipolytic inhibitor G0S2 modulates glioma stem-like cell radiation response.

J Exp Clin Cancer Res 2019 Apr 5;38(1):147. Epub 2019 Apr 5.

State Key Laboratory of Oncogenes and Related Genes, Renji-Med X Clinical Stem Cell Research Center, Ren Ji Hospital, Shanghai Cancer Institute, School of Medicine, Shanghai Jiao Tong University, Shanghai, 200127, China.

Background: Ionizing radiation (IR) therapy is the standard first-line treatment for newly diagnosed patients with glioblastoma (GBM), the most common and malignant primary brain tumor. However, the effects of IR are limited due to the aberrant radioresistance of GBM.

Methods: Transcriptome analysis was performed using RNA-seq in radioresistant patient-derived glioma stem-like cells (GSCs). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s13046-019-1151-xDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6451284PMC
April 2019
2 Reads

Gene signatures of quiescent glioblastoma cells reveal mesenchymal shift and interactions with niche microenvironment.

EBioMedicine 2019 Apr 2. Epub 2019 Apr 2.

Nash Family Department of Neuroscience, Friedman Brain Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA; Department of Neurosurgery, Icahn School of Medicine at Mount Sinai, New York, NY, USA. Electronic address:

Background: Glioblastoma (GBM), a highly malignant brain tumor, invariably recurs after therapy. Quiescent GBM cells represent a potential source of tumor recurrence, but little is known about their molecular underpinnings.

Methods: Patient-derived GBM cells were engineered by CRISPR/Cas9-assisted knock-in of an inducible histone2B-GFP (iH2B-GFP) reporter to track cell division history. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ebiom.2019.03.064DOI Listing
April 2019
2 Reads

Imaging flow cytometry facilitates multiparametric characterization of extracellular vesicles in malignant brain tumours.

J Extracell Vesicles 2019 21;8(1):1588555. Epub 2019 Mar 21.

Department of Neurosurgery, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.

Cells release heterogeneous nano-sized vesicles either as exosomes, being derived from endosomal compartments, or through budding from the plasma membrane as so-called microvesicles, commonly referred to as extracellular vesicles (EVs). EVs are known for their important roles in mammalian physiology and disease pathogenesis and provide a potential biomarker source in cancer patients. EVs are generally often analysed in bulk using Western blotting or by bead-based flow-cytometry or, with limited parameters, through nanoparticle tracking analysis. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/20013078.2019.1588555DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6442086PMC
March 2019
1 Read

Pediatric Brainstem Gliomas: A Retrospective Study of 180 Patients from the SEER Database.

Pediatr Neurosurg 2019 Apr 4:1-14. Epub 2019 Apr 4.

Department of Neurosurgery, Rush University Medical Center, Chicago, Illinois, USA.

Background/aims: Large population-based studies are needed to assess the epidemiology and survival risk factors associated with pediatric brainstem gliomas. This retrospective study explores factors that may influence survival in this population.

Methods: Utilizing the SEER database, the authors retrospectively assessed survival in histologically confirmed brainstem gliomas in patients aged 17 and younger. Read More

View Article

Download full-text PDF

Source
https://www.karger.com/Article/FullText/497440
Publisher Site
http://dx.doi.org/10.1159/000497440DOI Listing
April 2019
5 Reads

The landscape of the mesenchymal signature in brain tumours.

Brain 2019 Apr;142(4):847-866

Duke Preclinical Translational Unit, Duke University Medical Center, Durham, North Carolina.

The complexity of glioblastoma multiforme, the most common and lethal variant of gliomas, is reflected by cellular and molecular heterogeneity at both the inter- and intra-tumoural levels. Molecular subtyping has arisen in the past two decades as a promising strategy to give better predictions of glioblastoma multiforme evolution, common disease pathways, and rational treatment options. The Cancer Genome Atlas network initially identified four molecular subtypes of glioblastoma multiforme: proneural, neural, mesenchymal and classical. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/brain/awz044DOI Listing
April 2019
4 Reads

Cerebellopontine angle ependymoma in a young adult: A case report.

Medicine (Baltimore) 2019 Apr;98(14):e15019

Department of Neurosurgery, West China Hospital, Sichuan University, Chengdu, Sichuan, P. R. China.

Rationale: Cerebellopontine angle (CPA) ependymomas are atypical kind of ependymomas that characteristically occur in the pediatric age group. Therefore, finding a case of CPA ependymoma in a young male adult is not a common occurrence.

Patient Concerns: We present a case of a 28-year-old male who was involved in road traffic accident with suspected mild head injury. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/MD.0000000000015019DOI Listing
April 2019
4 Reads

Developmental origins and oncogenic pathways in malignant brain tumors.

Wiley Interdiscip Rev Dev Biol 2019 Apr 3:e342. Epub 2019 Apr 3.

Key Laboratory of Birth Defects and Related Diseases of Women and Children of Ministry of Education, Sichuan University, Chengdu, China.

Brain tumors such as adult glioblastomas and pediatric high-grade gliomas or medulloblastomas are among the leading causes of cancer-related deaths, exhibiting poor prognoses with little improvement in outcomes in the past several decades. These tumors are heterogeneous and can be initiated from various neural cell types, contributing to therapy resistance. How such heterogeneity arises is linked to the tumor cell of origin and their genetic alterations. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/wdev.342DOI Listing
April 2019
2 Reads

Extreme lateral supracerebellar infratentorial approach: how I do it.

Acta Neurochir (Wien) 2019 Apr 1. Epub 2019 Apr 1.

Department of Neurosurgery, University Hospital of Lausanne, Lausanne, Switzerland.

Background: The extreme lateral supracerebellar infratentorial (ELSI) approach was initially proposed to treat lesions of the posterolateral surface of the pons principally cavernomas. The versatility of the approach allowed its use for other pathologies like gliomas, aneurysms, epidermoids, and meningiomas.

Method: We describe here the ELSI approach along with its advantages and limits in comparison with other surgical approaches for the treatment of meningiomas of the petroclival region. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00701-019-03886-5DOI Listing

Diencephalic Syndrome as Presentation of Giant Childhood Craniopharyngioma: Management Review.

J Pediatr Neurosci 2018 Oct-Dec;13(4):383-387

Department of Neurosurgery, Neurosciences Centre, All India Institute of Medical Sciences, New Delhi, India.

Diencephalic syndrome (DES) is an extremely uncommon occurrence, and approximately 100 cases have been reported. It presents as a failure to thrive in infants and children but rarely occurs in adult population. The characteristic clinical features of DES include severely emaciated body, normal linear growth and normal or precocious intellectual development, hyperalertness, hyperkinesis, and euphoria usually associated with intracranial sellar-suprasellar mass lesion, usually optico-chiasmatic glioma or hypothalamic mass. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4103/JPN.JPN_179_17DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6413612PMC
April 2019
2 Reads

Mild thermotherapy and hyperbaric oxygen enhance sensitivity of TMZ/PSi nanoparticles via decreasing the stemness in glioma.

J Nanobiotechnology 2019 Apr 1;17(1):47. Epub 2019 Apr 1.

National Engineering Research Center for Nanomedicine, College of Life Science and Technology, Huazhong University of Science and Technology, No. 1037 Luoyu Road, Wuhan, 430074, People's Republic of China.

Background: Glioma is a common brain tumor with a high mortality rate. A small population of cells expressing stem-like cell markers in glioma contributes to drug resistance and tumor recurrence.

Methods: Porous silicon nanoparticles (PSi NPs) as photothermal therapy (PTT) agents loaded with TMZ (TMZ/PSi NPs), was combined with hyperbaric oxygen (HBO) therapy in vitro and in vivo. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s12951-019-0483-1DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6442425PMC
April 2019
3 Reads

Target identification reveals lanosterol synthase as a vulnerability in glioma.

Proc Natl Acad Sci U S A 2019 Apr 28;116(16):7957-7962. Epub 2019 Mar 28.

Laboratory of Chromatin Biology and Epigenetics, The Rockefeller University, New York, NY 10065;

Diffuse intrinsic pontine glioma (DIPG) remains an incurable childhood brain tumor for which novel therapeutic approaches are desperately needed. Previous studies have shown that the menin inhibitor MI-2 exhibits promising activity in preclinical DIPG and adult glioma models, although the mechanism underlying this activity is unknown. Here, using an integrated approach, we show that MI-2 exerts its antitumor activity in glioma largely independent of its ability to target menin. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1073/pnas.1820989116DOI Listing
April 2019
2 Reads

Mesenchymal stem cell therapies in brain disease.

Semin Cell Dev Biol 2019 Apr 3. Epub 2019 Apr 3.

Division of Hematology/Oncology, Department of Medicine, New Jersey Medical School, Rutgers Biomedical and Health Sciences, Newark, NJ, USA. Electronic address:

As treatments for diseases throughout the body progress, treatment for many brain diseases has been at a standstill due to difficulties in drug delivery. While new drugs are being discovered in vitro, these therapies are often hindered by inefficient tissue distribution and, more commonly, an inability to cross the blood brain barrier. Mesenchymal stem cells are thus being investigated as a delivery tool to directly target therapies to the brain to treat wide array of brain diseases. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.semcdb.2019.03.003DOI Listing
April 2019
2 Reads

PEDIATRIC HIGH GRADE GLIOMA: CLINICO-PATHOLOGICAL PROFILE, THERAPEUTIC APPROACHES AND FACTORS FOR OVERALL SURVIVAL.

Neurochirurgie 2019 Mar 25. Epub 2019 Mar 25.

Laboratoire d'Anatomie et de Cytologie Pathologique, CHU Habib Bourguiba, 3029 Sfax, Tunisia.

Introduction: Pediatric high grade gliomas are rare tumors of the central nervous system. Treatment is multidisciplinary, comprising surgical excision followed by radiotherapy and/or chemotherapy.

Objectives: To describe these tumors' characteristics as seen in our institution, and identify factors associated with better overall survival. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.neuchi.2019.03.001DOI Listing
March 2019
1 Read

APELA Expression in Glioma, and Its Association with Patient Survival and Tumor Grade.

Pharmaceuticals (Basel) 2019 Mar 26;12(1). Epub 2019 Mar 26.

Department of Pathology and the Center for Cancer Research, University of Tennessee Health Science Center, Memphis, TN 38163, USA.

Glioblastoma (GBM) is the most common and deadliest primary adult brain tumor. Invasion, resistance to therapy, and tumor recurrence in GBM can be attributed in part to brain tumor-initiating cells (BTICs). BTICs isolated from various patient-derived xenografts showed high expression of the poorly characterized Apelin early ligand A (APELA) gene. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3390/ph12010045DOI Listing
March 2019
2 Reads

Indocyanine-Green for Fluorescence-Guided Surgery of Brain Tumors: Evidence, Techniques, and Practical Experience.

Front Surg 2019 12;6:11. Epub 2019 Mar 12.

Department of Neurosurgery at the Hospital of the University of Pennsylvania, Philadelphia, PA, United States.

The primary treatment for brain tumors often involves surgical resection for diagnosis, relief of mass effect, and prolonged survival. In neurosurgery, it is of utmost importance to achieve maximal safe resection while minimizing iatrogenic neurologic deficit. Thus, neurosurgeons often rely on extra tools in the operating room, such as neuronavigation, intraoperative magnetic resonance imaging, and/or intraoperative rapid pathology. Read More

View Article

Download full-text PDF

Source
https://www.frontiersin.org/article/10.3389/fsurg.2019.00011
Publisher Site
http://dx.doi.org/10.3389/fsurg.2019.00011DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6422908PMC
March 2019
8 Reads

MiR-21, miR-34a, miR-125b, miR-181d and miR-648 levels inversely correlate with MGMT and TP53 expression in primary glioblastoma patients.

Arch Med Sci 2019 Mar 31;15(2):504-512. Epub 2017 Jul 31.

Department of Genetics, Chair of Molecular Medicine, Faculty of Medicine, University of Rzeszow, Rzeszow, Poland.

Introduction: and alterations play a crucial role in glioblastoma (GB) pathogenesis. and function is affected by several pathologic mechanisms, such as point mutations or promoter methylation, which are well characterized. Expression of both genes can be regulated by other mechanisms as well, e. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.5114/aoms.2017.69374DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6425218PMC
March 2019
2 Reads

Modeling Patient-Derived Glioblastoma with Cerebral Organoids.

Cell Rep 2019 Mar;26(12):3203-3211.e5

Meyer Cancer Center, Division of Neuro-Oncology, Department of Neurology, NewYork-Presbyterian Hospital/Weill Cornell Medicine, New York, NY, USA. Electronic address:

The prognosis of patients with glioblastoma (GBM) remains dismal, with a median survival of approximately 15 months. Current preclinical GBM models are limited by the lack of a "normal" human microenvironment and the inability of many tumor cell lines to accurately reproduce GBM biology. To address these limitations, we have established a model system whereby we can retro-engineer patient-specific GBMs using patient-derived glioma stem cells (GSCs) and human embryonic stem cell (hESC)-derived cerebral organoids. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.celrep.2019.02.063DOI Listing
March 2019
3 Reads

ROS generation and autophagosome accumulation contribute to the DMAMCL-induced inhibition of glioma cell proliferation by regulating the ROS/MAPK signaling pathway and suppressing the Akt/mTOR signaling pathway.

Onco Targets Ther 2019 7;12:1867-1880. Epub 2019 Mar 7.

Department of Neurosurgery, Shandong Provincial Hospital Affiliated to Shandong University, Jinan, 250021, Shandong, China,

Purpose: Chemotherapy after surgery can prolong the survival of patients with gliomas. Dimethylaminomicheliolide (DMAMCL), a novel chemotherapeutic agent, exhibited antitumor properties in acute myeloid leukemia stem cells and showed an increased drug concentration in the brain. This study aims to investigate the specific anticancer activities and mechanisms of DMAMCL in glioma cells. Read More

View Article

Download full-text PDF

Source
https://www.dovepress.com/ros-generation-and-autophagosome-a
Publisher Site
http://dx.doi.org/10.2147/OTT.S195329DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6413739PMC
March 2019
13 Reads

Elevated signature of a gene module coexpressed with CDC20 marks genomic instability in glioma.

Proc Natl Acad Sci U S A 2019 Apr 15;116(14):6975-6984. Epub 2019 Mar 15.

Beijing Key Laboratory of Gene Resource and Molecular Development, Laboratory of Neuroscience and Brain Development, Beijing Normal University, 100875 Beijing, China;

Genomic instability (GI) drives tumor heterogeneity and promotes tumor progression and therapy resistance. However, causative factors underlying GI and means for clinical detection of GI in glioma are inadequately identified. We describe here that elevated expression of a gene module coexpressed with CDC20 (CDC20-M), the activator of the anaphase-promoting complex in the cell cycle, marks GI in glioma. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1073/pnas.1814060116DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6452696PMC
April 2019
2 Reads
9.809 Impact Factor

AQP4 aggregation state is a determinant for glioma cell fate.

Cancer Res 2019 Mar 15. Epub 2019 Mar 15.

Dept of Bioscience, Biotechnology and Biopharmaceutics, University of Bari Aldo Moro

The glial water channel protein aquaporin-4 (AQP4) forms heterotetramers in the plasma membrane made of the M23-AQP4 and M1-AQP4 isoforms. The isoform ratio controls AQP4 aggregation into supramolecular structures called orthogonal arrays of particles (AQP4-OAP). The role of AQP4 aggregation into OAP in malignant gliomas is still unclear. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/0008-5472.CAN-18-2015DOI Listing
March 2019
1 Read

MicroRNA-451 Inhibits Migration of Glioblastoma while Making It More Susceptible to Conventional Therapy.

Noncoding RNA 2019 Mar 15;5(1). Epub 2019 Mar 15.

Department of Neurosurgery, Harvey Cushing Neuro-oncology Laboratories, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, USA.

Malignant glioblastoma (GBM, glioma) is the most common and aggressive primary adult brain tumor. The prognosis of GBM patients remains poor, despite surgery, radiation and chemotherapy. The major obstacles for successful remedy are invasiveness and therapy resistance of GBM cells. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3390/ncrna5010025DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6468936PMC
March 2019
1 Read

Current Murine Models and New Developments in H3K27M Diffuse Midline Gliomas.

Front Oncol 2019 27;9:92. Epub 2019 Feb 27.

Department of Neurosurgery, Mayo Clinic, Rochester, MN, United States.

Diffuse Midline Gliomas with Histone 3-Lysine-27-Methionine (H3K27M) mutation constitute the majority of Diffuse Intrinsic Pontine Glioma (DIPG), which is the most aggressive form of pediatric glioma with a dire prognosis. DIPG are lethal tumors found in younger children with a median survival <1 year from diagnosis. Discovery of the characteristic H3K27M mutations offers opportunity and hope for development of targeted therapies for this deadly disease. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3389/fonc.2019.00092DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6400847PMC
February 2019
3 Reads

Arsenic Trioxide and (-)-Gossypol Synergistically Target Glioma Stem-Like Cells via Inhibition of Hedgehog and Notch Signaling.

Cancers (Basel) 2019 Mar 12;11(3). Epub 2019 Mar 12.

Experimental Neurosurgery, Department of Neurosurgery, Neuroscience Center, Goethe University Hospital, 60528 Frankfurt am Main, Germany.

Glioblastoma is one of the deadliest malignancies and is virtually incurable. Accumulating evidence indicates that a small population of cells with a stem-like phenotype is the major culprit of tumor recurrence. Enhanced DNA repair capacity and expression of stemness marker genes are the main characteristics of these cells. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3390/cancers11030350DOI Listing
March 2019
1 Read

The lncRNA TP73-AS1 is linked to aggressiveness in glioblastoma and promotes temozolomide resistance in glioblastoma cancer stem cells.

Cell Death Dis 2019 Mar 13;10(3):246. Epub 2019 Mar 13.

Department of Life Sciences, Ben-Gurion University of the Negev, Beer-Sheva, Israel.

Glioblastoma multiform (GBM) is the most common brain tumor characterized by a dismal prognosis. GBM cancer stem cells (gCSC) or tumor-initiating cells are the cell population within the tumor-driving therapy resistance and recurrence. While temozolomide (TMZ), an alkylating agent, constitutes the first-line chemotherapeutic significantly improving survival in GBM patients, resistance against this compound commonly leads to GBM recurrence and treatment failure. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41419-019-1477-5DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6416247PMC
March 2019
1 Read

Proteins of the Wnt signaling pathway as targets for the regulation of CD133+ cancer stem cells in glioblastoma.

Oncol Rep 2019 May 5;41(5):3080-3088. Epub 2019 Mar 5.

School of Biomedicine, Far Eastern Federal University, Vladivostok 690091, Russia.

Glioblastoma multiforme (GBM) is one of the most aggressive types of brain tumor and is highly resistant to therapy. The median survival time for patients with GBM is 15 months. GBM resistance to treatment is associated with cancer stem cells (CSCs). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3892/or.2019.7043DOI Listing
May 2019
1 Read

Therapeutic potential of curcumin in the treatment of glioblastoma multiforme.

Curr Pharm Des 2019 Mar 13. Epub 2019 Mar 13.

Neurogenic Inflammation Research Center, Mashhad University of Medical Sciences, Mashhad. Iran.

Glioblastoma multiforme (GBM) is the most common primary malignant brain tumor. Despite standard multimodality treatment, the highly aggressive nature of GBM makes it one of the deadliest human malignancies. The anti-cancer effects of dietary phytochemicals like curcumin provides new insights to cancer treatment. Read More

View Article

Download full-text PDF

Source
http://www.eurekaselect.com/170681/article
Publisher Site
http://dx.doi.org/10.2174/1381612825666190313123704DOI Listing
March 2019
5 Reads
3.452 Impact Factor

Treatment of adult brainstem glioma with combined antiangiogenic therapy: a case report and literature review.

Onco Targets Ther 2019 18;12:1333-1339. Epub 2019 Feb 18.

Department of Radiation Oncology, Allegheny General Hospital, Pittsburgh, PA, USA.

Adult brainstem gliomas belong to a rare and heterogeneous group of brain tumors. The overall prognosis is poor; therapeutic options are limited, given the resistance to radiotherapy and the unclear role of chemotherapy/antiangiogenic therapy. Apatinib, a tyrosine kinase inhibitor that selectively inhibits the vascular endothelial growth factor receptor and mildly inhibits c-Kit, PDGFR-β, RET, and c-SRC, has been reported to show efficacy among some patients with malignant supratentorial gliomas. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2147/OTT.S195783DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6388961PMC
February 2019
3 Reads

Gold quantum dots impair the tumorigenic potential of glioma stem-like cells via β-catenin downregulation in vitro.

Int J Nanomedicine 2019 13;14:1131-1148. Epub 2019 Feb 13.

Zoology Department, College of Science, King Saud University, Riyadh 11451, Saudi Arabia,

Background: Over the past several decades, the incidence of solid cancers has rapidly increased worldwide. Successful removal of tumor-initiating cells within tumors is essential in the field of cancer therapeutics to improve patient disease-free survival rates. The biocompatible multivarient-sized gold nanoparticles (MVS-GNPs) from quantum dots (QDs, <10 nm) to nanosized (up to 50 nm) particles have vast applications in various biomedical areas including cancer treatment. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2147/IJN.S195333DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6391154PMC

Changing paradigms in the surgical management of brainstem gliomas. Lessons learnt from Prof Nagpal's paper published in 1983.

Neurol India 2019 Jan-Feb;67(1):20-36

Department of Neurosurgery, Institute of Neurosciences, SRM Institutes for Medical Sciences, Vadapalani, Chennai, Tamil Nadu, India.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4103/0028-3886.253617DOI Listing

Sustained NF-κB-STAT3 signaling promotes resistance to Smac mimetics in Glioma stem-like cells but creates a vulnerability to EZH2 inhibition.

Cell Death Discov 2019 4;5:72. Epub 2019 Mar 4.

1Department of Neurology, Massachusetts General Hospital, Boston, MA USA.

Glioblastoma is an incurable and highly aggressive brain tumor. Understanding therapeutic resistance and survival mechanisms driving this tumor type is key to finding effective therapies. Smac mimetics (SM) emerged as attractive cancer therapeutics particularly for tumor populations that are highly resistant to conventional apoptosis-inducing therapies. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41420-019-0155-9DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6399311PMC
March 2019
1 Read

Brainstem Gliomas: New Models Recapitulate Human Disease and Deepen Our Understanding.

Neurosurgery 2019 Mar 8. Epub 2019 Mar 8.

Department of Neurosurgery University of Southern California Keck School of Medicine Los Angeles, California.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/neuros/nyz033DOI Listing
March 2019
1 Read

High density is a property of slow-cycling and treatment-resistant human glioblastoma cells.

Exp Cell Res 2019 May 5;378(1):76-86. Epub 2019 Mar 5.

Department of Neurology, University of California, San Francisco, CA 94158, United States; Weill Institute for Neurosciences, University of California, San Francisco, CA 94158, United States; Department of Neurological Surgery and Brain Tumor Center, University of California, San Francisco, CA 94158, United States; Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, CA 94158, United States. Electronic address:

Slow-cycling and treatment-resistant cancer cells escape therapy, providing a rationale for regrowth and recurrence in patients. Much interest has focused on identifying the properties of slow-cycling tumor cells in glioblastoma (GBM), the most common and lethal primary brain tumor. Despite aggressive ionizing radiation (IR) and treatment with the alkylating agent temozolomide (TMZ), GBM patients invariably relapse and ultimately succumb to the disease. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.yexcr.2019.03.003DOI Listing
May 2019
7 Reads

Quantitative Evaluation of Intraventricular Delivery of Therapeutic Neural Stem Cells to Orthotopic Glioma.

Front Oncol 2019 19;9:68. Epub 2019 Feb 19.

Department of Developmental and Stem Cell Biology, Beckman Research Institute of City of Hope, Duarte, CA, United States.

Neural stem cells (NSCs) are inherently tumor-tropic, which allows them to migrate through normal tissue and selectively localize to invasive tumor sites in the brain. We have engineered a clonal, immortalized allogeneic NSC line (HB1.F3. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3389/fonc.2019.00068DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6389659PMC
February 2019
3 Reads

ACVR1 R206H cooperates with H3.1K27M in promoting diffuse intrinsic pontine glioma pathogenesis.

Nat Commun 2019 03 4;10(1):1023. Epub 2019 Mar 4.

Department of Pediatrics, Northwestern University, Chicago, IL, 60611, USA.

Diffuse intrinsic pontine glioma (DIPG) is an incurable pediatric brain tumor, with approximately 25% of DIPGs harboring activating ACVR1 mutations that commonly co-associate with H3.1K27M mutations. Here we show that in vitro expression of ACVR1 R206H with and without H3. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41467-019-08823-9DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6399349PMC
March 2019
1 Read

Role of Notch Signaling Pathway in Glioblastoma Pathogenesis.

Cancers (Basel) 2019 03 1;11(3). Epub 2019 Mar 1.

NeuroMi, Milan Center for Neuroscience, Department of Neurology and Neuroscience, San Gerardo Hospital, University of Milano-Bicocca, 20900 Monza, Italy.

Notch signaling is an evolutionarily conserved pathway that regulates important biological processes, such as cell proliferation, apoptosis, migration, self-renewal, and differentiation. In mammals, Notch signaling is composed of four receptors (Notch1⁻4) and five ligands (Dll1-3⁻4, Jagged1⁻2) that mainly contribute to the development and maintenance of the central nervous system (CNS). Neural stem cells (NSCs) are the starting point for neurogenesis and other neurological functions, representing an essential aspect for the homeostasis of the CNS. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3390/cancers11030292DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6468848PMC
March 2019
2 Reads

[Clinicopathological characteristics and prognosis of diffuse midline gliomas with histone H3K27M mutation: an analysis of 30 cases].

Zhonghua Bing Li Xue Za Zhi 2019 Mar;48(3):192-198

Department of Pathology, Guangdong Provincial People's Hospital, Guangzhou 510080, China.

To analyze the clinicopathological characteristics and prognosis of diffuse midline glioma (DMG) with H3K27M mutation. Thirty cases of DMG were collected in Guangdong Sanjiu Brain Hospital from October 2016 to May 2018. The patients' clinicopathological data including age, tumor site and histological grade, treatment and follow-up data were collected and analyzed. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3760/cma.j.issn.0529-5807.2019.03.005DOI Listing
March 2019
1 Read